No Data
No Data
No Data
No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $105 Price Target
BenzingaApr 26 07:06 ET
Praxis Precision Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 98.56% HC Wainwright & Co. → $105 Reiterates Buy → Buy 03/26/2024 142.06% Jefferies $75 → $128
BenzingaApr 26 07:05 ET
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
TipRanksApr 26 06:20 ET
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous
GlobeNewswireApr 12 08:00 ET
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
Yahoo FinanceApr 11 12:00 ET
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating
10:26 AM EDT, 04/08/2024 (MT Newswires) -- Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating Price: 51.07, Change
MT NewswiresApr 8 10:26 ET
No Data
No Data
BarfBag : Check out $Pagaya Technologies (PGY.US)$ solid AH